Form 4: Akari Therapeutics CEO Boosts Stake with Significant ADS Purchase

Akari Therapeutics Plc's CEO and Director, Abizer Gaslightwala, acquired 20,000 American Depositary Shares (ADS) for $25,400, increasing his beneficial ownership to 201,428 ADS.

Summary

• Abizer Gaslightwala, CEO and Director of Akari Therapeutics Plc (AKTX), acquired 20,000 American Depositary Shares (ADS) on June 10, 2025.
• The acquisition was made at an average price of $1.27 per ADS, totaling $25,400.
• Following this transaction, Mr. Gaslightwala's direct beneficial ownership of Akari Therapeutics ADS increased to 201,428.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares of Akari Therapeutics Plc.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the CEO's direct purchase of company shares, indicating strong insider confidence in Akari Therapeutics' prospects.

Positives

• The acquisition of shares by the CEO signals strong management confidence in the company's future prospects and valuation.
• Insider buying can often be interpreted by the market as a positive indicator, suggesting that those closest to the company believe the stock is undervalued or poised for growth.

Related Party Transactions

• The transaction involves the acquisition of company securities by a key executive (CEO and Director), which is a direct related-party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign, potentially increasing investor confidence and demand for the stock.
• Employees may also perceive this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

Keywords

Akari Therapeutics, AKTX, Abizer Gaslightwala, Insider Buying, Form 4, SEC Filing, American Depositary Shares, ADS, CEO Stock Purchase, Biotechnology, Pharmaceuticals